Pardeep S Jhund

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9243476/publications.pdf

Version: 2024-02-01

252 papers	21,775 citations	11608 70 h-index	10708 138 g-index
263 all docs	263 docs citations	263 times ranked	17146 citing authors

#	Article	IF	Citations
1	High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis. Cardiovascular Research, 2023, 119, 213-220.	1.8	7
2	Reninâ€“angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 165-178.	1.4	40
3	Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in <scp>EMPHASISâ€HF</scp> and <scp>RALES</scp>. European Journal of Heart Failure, 2022, 24, 529-538.	2.9	7
4	Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation, 2022, 145, 158-169.	1.6	18
5	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology,the, 2022, 10, 24-34.	5.5	40
6	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 513-525.	2.9	33
7	Effect of sacubitril/valsartan on investigatorâ€reported ventricular arrhythmias in <scp>PARADIGMâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 551-561.	2.9	20
8	Diabetes and preâ€diabetes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, 2022, 24, 497-509.	2.9	30
9	<scp>Angiotensinâ€“neprilysin</scp> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. European Journal of Heart Failure, 2022, 24, 1591-1598.	2.9	14
10	Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2022, 24, 1066-1076.	2.9	28
11	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk inÂDAPA-HF. JACC: Heart Failure, 2022, 10, 104-118.	1.9	5
12	Drug therapy for heart failure with reduced ejection fraction: what is the â€˜rightâ€™ dose?. European Journal of Heart Failure, 2022, 24, 421-430.	2.9	9
13	Bringing FIDELITY to the estimate of treatment effects of finerenone in chronic kidney disease due to type 2 diabetes. European Heart Journal, 2022, 43, 485-487.	1.0	6
14	Effects of Dapagliflozin in Asian Patients With HeartÂFailure and Reduced Ejection Fraction in DAPA-HF. JACC Asia, 2022, , .	0.5	2
15	Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 2022, 24, 861-866.	2.9	7
16	Age-Adjusted Survival Extrapolationsâ€”Results May Differ From Those Generated by the Weibull Modelâ€”Reply. JAMA Cardiology, 2022, , .	3.0	0
17	Clinical Outcomes Related to Background Diuretic Use and New Diuretic Initiation in Patients With HFrEF. JACC: Heart Failure, 2022, 10, 415-427.	1.9	4
18	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation, 2022, 146, 438-449.	1.6	53

#	Article	IF	Citations
19	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. Annals of Internal Medicine, 2022, 175, 820-830.	2.0	56
20	Apparent Treatment-Resistant Hypertension Across the Spectrum of HeartÂFailure Phenotypes in the SwedishÂHF Registry. JACC: Heart Failure, 2022, 10, 380-392.	1.9	5
21	Quantifying Treatment Effects in Trials with Multiple Event-Time Outcomes. , 2022, 1, .		10
22	Effects of Dapagliflozin According to the HeartÂFailure Collaboratory Medical Therapy Score. JACC: Heart Failure, 2022, 10, 543-555.	1.9	7
23	Within trial comparison of survival time projections from shortâ€term followâ€up with longâ€term followâ€up findings. ESC Heart Failure, 2022, 9, 3655-3658.	1.4	2
24	Machine Learningâ€“Based Models Incorporating Social Determinants of Health vs Traditional Models for Predicting In-Hospital Mortality in Patients With Heart Failure. JAMA Cardiology, 2022, 7, 844.	3.0	28
25	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Circulation, 2021, 143, 516-525.	1.6	237
26	Adherence to prescribed medications in patients with heart failure: insights from liquid chromatographyâ€“tandem mass spectrometry-based urine analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 296-301.	1.4	12
27	Anticoagulation, atherothrombosis, and heart failure: lessons from COMMANDER-HF and CORONA. European Heart Journal, 2021, 42, e5-e7.	1.0	2
28	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. Circulation, 2021, 143, 298-309.	1.6	193
29	Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 2021, 8, 129-138.	1.4	9
30	The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. European Heart Journal, 2021, 42, 1199-1202.	1.0	24
31	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2021, 23, 632-643.	2.9	24
32	Risk stratification in patients presenting with acute heart failure. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 113-115.	0.4	0
33	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGMâ€HF. Journal of the American Heart Association, 2021, 10, e019238.	1.6	20
34	Effect of dapagliflozin on anaemia in <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2021, 23, 617-628.	2.9	57
35	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the <scp>DAPAâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 601-613.	2.9	33
36	Global Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2021, 14, e007901.	1.6	25

#	Article	IF	Citations
37	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. JACC: Heart Failure, 2021, 9, 254-264.	1.9	75
38	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <scp>Heart Failure Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2021, 23, 872-881.	2.9	160
39	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. Circulation, 2021, 143, 1962-1972.	1.6	35
40	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 499.	3.0	120
41	Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 678.	3.0	26
42	Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2021, 6, 1130.	3.0	114
43	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. Clinical Research in Cardiology, 2021, 110, 1334-1349.	1.5	4
44	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiology, 2021, 6, 1298-1305.	3.0	12
45	Effect of Neprilysin Inhibition on Left Ventricular Remodeling in Patients With Asymptomatic Left Ventricular Systolic Dysfunction Late After Myocardial Infarction. Circulation, 2021, 144, 199-209.	1.6	40
46	The â€˜Peptide for Lifeâ€™ Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across <scp>Europe</scp>. European Journal of Heart Failure, 2021, 23, 1432-1436.	2.9	10
47	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 2021, 23, 1662-1672.	2.9	36
48	Derivation and Validation of a 10-Year Risk Score for Symptomatic Abdominal Aortic Aneurysm: Cohort Study of Nearly 500 000 Individuals. Circulation, 2021, 144, 604-614.	1.6	9
49	Sacubitrilâ€“valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. European Heart Journal, 2021, 42, 3741-3752.	1.0	74
50	Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer. PLoS ONE, 2021, 16, e0255364.	1.1	3
51	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 2021, 42, 3727-3738.	1.0	125
52	Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. Kidney360, 2021, 2, 10.34067/KID.0004272021.	0.9	7
53	Integrating High-Sensitivity Troponin T andÂSacubitril/Valsartan Treatment inÂHFpEF. JACC: Heart Failure, 2021, 9, 627-635.	1.9	21
54	Resistance to antihypertensive treatment and longâ€term risk: The Atherosclerosis Risk in Communities study. Journal of Clinical Hypertension, 2021, 23, 1887-1896.	1.0	7

#	Article	IF	Citations
55	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Diabetes Care, 2021, 44, 586-594.	4.3	50
56	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGONâ€HF. Journal of the American Heart Association, 2021, 10, e021494.	1.6	13
57	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. Circulation: Heart Failure, 2021, 14, CIRCHEARTFAILURE121008837.	1.6	21
58	Response by Lee et al to Letter Regarding Article, â€œEffect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)â€• Circulation, 2021, 144, e40.	1.6	6
59	Healthcare disparities for women hospitalized with myocardial infarction and angina. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 156-165.	1.8	16
60	Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in HeartÂFailure With Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 188-198.	1.9	38
61	The recurring problem of heart failure hospitalisations. European Journal of Heart Failure, 2020, 22, 249-250.	2.9	5
62	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. Circulation, 2020, 141, 100-111.	1.6	145
63	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 141, 90-99.	1.6	244
64	Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction. Circulation, 2020, 141, 338-351.	1.6	244
65	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2020, 22, 528-538.	2.9	28
66	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucoseâ€lowering drugs in patients with heart failure. European Journal of Heart Failure, 2020, 22, 196-213.	2.9	131
67	Therapeutic futility and phenotypic heterogeneity in heart failure with preserved ejection fraction: what is the role of bionic learning?. European Journal of Heart Failure, 2020, 22, 159-161.	2.9	4
68	Glycated Hemoglobin, Prediabetes, and the Links to Cardiovascular Disease: Data From UK Biobank. Diabetes Care, 2020, 43, 440-445.	4.3	56
69	Estimating the Lifetime Benefits of Treatments for HeartÂFailure. JACC: Heart Failure, 2020, 8, 984-995.	1.9	15
70	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodiumâ€“glucose coâ€transporter 2 inhibitors in heart failure. European Journal of Heart Failure, 2020, 22, 1984-1986.	2.9	66
71	Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGMâ€HF. ESC Heart Failure, 2020, 7, 3355-3364.	1.4	9
72	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. Circulation, 2020, 142, 1040-1054.	1.6	128

#	Article	IF	Citations
73	The Global Ambulatory Blood Pressure Monitoring (ABPM) in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry. Rationale, design and objectives. Journal of Human Hypertension, 2020, 35, 1029-1037.	1.0	10
74	Vericiguat in HeartÂFailure With Reduced Ejection Fraction With High Natriuretic Peptides. JACC: Heart Failure, 2020, 8, 940-942.	1.9	2
75	Prevalence and incidence of intraâ€ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGMâ€HF and ATMOSPHERE. European Journal of Heart Failure, 2020, 22, 2370-2379.	2.9	14
76	Costâ€effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational healthâ€economic analysis of <scp>DAPAâ€HF</scp>. European Journal of Heart Failure, 2020, 22, 2147-2156.	2.9	91
77	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. Diabetes Care, 2020, 43, 2878-2881.	4.3	20
78	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2020, 142, 1623-1632.	1.6	51
79	NTâ€proBNP by Itself Predicts Death and Cardiovascular Events in Highâ€Risk Patients With Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2020, 9, e017462.	1.6	34
80	Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction. Circulation, 2020, 142, 1236-1245.	1.6	81
81	Serum potassium in the <scp>PARADIGMâ€HF</scp> trial. European Journal of Heart Failure, 2020, 22, 2056-2064.	2.9	34
82	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). European Heart Journal, 2020, 41, 3402-3418.	1.0	90
83	A Randomized Trial Comparing The Effect Of Sacubitril/Valsartan To Valsartan On Left Ventricular Remodeling In Patients With Asymptomatic Left Ventricular Systolic Dysfunction After Myocardial Infarction. Journal of Cardiac Failure, 2020, 26, 1110.	0.7	0
84	Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure. Circulation: Heart Failure, 2020, 13, e007879.	1.6	14
85	<scp>VICTORIA</scp> in context. European Journal of Heart Failure, 2020, 22, 1747-1751.	2.9	2
86	Myocardial Infarction in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 618-626.	1.9	17
87	Efficacy and safety of sodiumâ€“glucose coâ€transporter 2 inhibition according to left ventricular ejection fraction in DAPAâ€HF. European Journal of Heart Failure, 2020, 22, 1247-1258.	2.9	29
88	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA - Journal of the American Medical Association, 2020, 323, 1353.	3.8	340
89	Covariate adjusted reanalysis of the I-Preserve trial. Clinical Research in Cardiology, 2020, 109, 1358-1365.	1.5	11
90	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 2020, 41, 2379-2392.	1.0	151

#	Article	IF	Citations
91	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in HeartÂFailure With Preserved Ejection Fraction. JACC: Heart Failure, 2020, 8, 372-381.	1.9	53
92	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan. JACC: Heart Failure, 2020, 8, 811-818.	1.9	87
93	Sodiumâ€“glucose coâ€transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1495-1503.	2.9	100
94	Response by Jackson et al to Letter Regarding Article, â€œEffects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HFâ€• Circulation, 2020, 142, e5-e6.	1.6	10
95	Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006541.	1.6	96
96	Predictors of sudden cardiac death in highâ€risk patients following a myocardial infarction. European Journal of Heart Failure, 2020, 22, 848-855.	2.9	14
97	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. JAMA Cardiology, 2020, 5, 432.	3.0	59
98	Dyslipidaemia, a factor worthy of adjustment: reply. European Journal of Heart Failure, 2020, 22, 564-565.	2.9	0
99	The prevalence and importance of frailty in heart failure with reduced ejection fractionÂâ€“Âan analysis of <scp>PARADIGMâ€HF</scp> and <scp>ATMOSPHERE</scp>. European Journal of Heart Failure, 2020, 22, 2123-2133.	2.9	85
100	A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. European Heart Journal, 2020, 41, 2356-2362.	1.0	38
101	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet, The, 2020, 396, 121-128.	6.3	376
102	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 776-785.	5.5	961
103	Heart Failure with Reduced Ejection Fraction. , 2019, , 383-395.		0
104	Response by Welsh et al to Letter Regarding Article â€œUrinary Sodium Excretion, Blood Pressure, and Risk of Future Cardiovascular Disease and Mortality in Subjects Without Prior Cardiovascular Diseaseâ€• Hypertension, 2019, 74, e27-e28.	1.3	2
105	Age-Related Characteristics and Outcomes of Patients With HeartÂFailure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 601-612.	1.2	97
106	Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. European Journal of Heart Failure, 2019, 21, 974-984.	2.9	52
107	Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease. Nature Medicine, 2019, 25, 1753-1760.	15.2	174
108	Angiotensinâ€“Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 2019, 381, 1609-1620.	13.9	1,485

#	Article	IF	Citations
109	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction. Circulation, 2019, 140, 1369-1379.	1.6	74
110	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019, 381, 1995-2008.	13.9	4,108
111	CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy. JACC: Heart Failure, 2019, 7, 878-887.	1.9	37
112	Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. European Journal of Heart Failure, 2019, 21, 844-851.	2.9	91
113	Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease. Circulation, 2019, 140, 542-552.	1.6	118
114	Outcomes and Effect of Treatment According to Etiology in HFrEF. JACC: Heart Failure, 2019, 7, 457-465.	1.9	94
115	Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2019, 7, 418-427.	1.9	20
116	Improving recruitment for clinical trials: the human touch. Medical Journal of Australia, 2019, 210, 401-402.	0.8	0
117	PREVALENCE AND PREDICTORS OF MYOCARDIAL RECOVERY IN PERIPARTUM CARDIOMYOPATHY: A SYSTEMATIC REVIEW. Journal of the American College of Cardiology, 2019, 73, 842.	1.2	0
118	N-Terminal Pro-B-Type Natriuretic Peptide Levels for Risk Prediction in Patients With Heart Failure and Preserved Ejection Fraction According to Atrial Fibrillation Status. Circulation: Heart Failure, 2019, 12, e005766.	1.6	21
119	Urinary Sodium Excretion, Blood Pressure, and Risk of Future Cardiovascular Disease and Mortality in Subjects Without Prior Cardiovascular Disease. Hypertension, 2019, 73, 1202-1209.	1.3	54
120	Income Inequality and Outcomes in HeartÂFailure. JACC: Heart Failure, 2019, 7, 336-346.	1.9	63
121	Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction. Clinical Research in Cardiology, 2019, 108, 868-877.	1.5	11
122	The price of a failing heart. European Journal of Heart Failure, 2019, 21, 1532-1533.	2.9	0
123	Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure, 2019, 12, e006539.	1.6	78
124	Physiological monitoring of the complex multimorbid heart failure patient â€“ diabetes and monitoring glucose control. European Heart Journal Supplements, 2019, 21, M20-M24.	0.0	0
125	Prevalence and profile of â€œseasonal frequent flyersâ€•with chronic heart disease: Analysis of 1598 patients and 4588 patient-years follow-up. International Journal of Cardiology, 2019, 279, 126-132.	0.8	3
126	Differential Impact of Heart Failure WithÂReduced Ejection Fraction onÂMenÂandÂWomen. Journal of the American College of Cardiology, 2019, 73, 29-40.	1.2	168

#	Article	IF	Citations
127	Diabetic cardiomyopathy. Heart, 2019, 105, 337-345.	1.2	60
128	Contemporary Management of Heart Failure in the Elderly. Drugs and Aging, 2019, 36, 137-146.	1.3	8
129	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. European Journal of Heart Failure, 2019, 21, 577-587.	2.9	38
130	The prognostic value of troponin T and Nâ€terminal pro Bâ€type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes. European Journal of Heart Failure, 2019, 21, 40-49.	2.9	54
131	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. European Journal of Heart Failure, 2018, 20, 888-895.	2.9	93
132	Effect of digoxin in patients with heart failure and midâ€range (borderline) left ventricular ejection fraction. European Journal of Heart Failure, 2018, 20, 1139-1145.	2.9	45
133	Association of Total and Differential Leukocyte Counts With Cardiovascular Disease and Mortality in the UK Biobank. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 1415-1423.	1.1	69
134	Risk of Incident Heart Failure in Patients With Diabetes and Asymptomatic Left Ventricular Systolic Dysfunction. Diabetes Care, 2018, 41, 1285-1291.	4.3	38
135	Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC: Heart Failure, 2018, 6, 489-498.	1.9	272
136	Heart failure with midâ€range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. European Journal of Heart Failure, 2018, 20, 1230-1239.	2.9	295
137	Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGMâ€HF). European Journal of Heart Failure, 2018, 20, 760-768.	2.9	62
138	Microvascular complications in diabetes patients with heart failure and reduced ejection fractionâ€"insights from the Betaâ€blocker Evaluation of Survival Trial. European Journal of Heart Failure, 2018, 20, 1549-1556.	2.9	17
139	Analysing registries in heart failure: The case of angiotensin receptor blockers in Asians with heart failure with reduced ejection fraction. International Journal of Cardiology, 2018, 257, 224-225.	0.8	0
140	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the <scp>ATMOSPHERE</scp> trial. European Journal of Heart Failure, 2018, 20, 136-147.	2.9	18
141	Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. European Journal of Heart Failure, 2018, 20, 295-303.	2.9	65
142	Evidence-Based Therapy and Its Association With Workforce Detachment After First Hospitalization for Heart Failure. JACC: Heart Failure, 2018, 6, 41-48.	1.9	3
143	Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGMâ€HF. European Journal of Heart Failure, 2018, 20, 514-522.	2.9	35
144	Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart, 2018, 104, 144-150.	1.2	61

#	Article	IF	Citations
145	Peripartum cardiomyopathy: diagnosis and management. Heart, 2018, 104, 779-786.	1.2	14
146	Employment status at time of first hospitalization for heart failure is associated with a higher risk of death and rehospitalization for heart failure. European Journal of Heart Failure, 2018, 20, 240-247.	2.9	16
147	Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early?. Heart, 2018, 104, 1812-1813.	1.2	1
148	Which patients with heart failure should receive specialist palliative care?. European Journal of Heart Failure, 2018, 20, 1338-1347.	2.9	60
149	Incidence of Hospitalization for Heart Failure and Case-Fatality Among 3.25 Million People With and Without Diabetes Mellitus. Circulation, 2018, 138, 2774-2786.	1.6	139
150	Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study. Clinical Epidemiology, 2018, Volume 10, 917-930.	1.5	10
151	Association is not causation: treatment effects cannot be estimated from observational data in heart failure. European Heart Journal, 2018, 39, 3417-3438.	1.0	42
152	How robust are clinical trials in heart failure?. European Heart Journal, 2017, 38, ehw427.	1.0	49
153	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. European Heart Journal, 2017, 38, ehw509.	1.0	36
154	Dynamic changes and prognostic value of pulmonary congestion by lung ultrasound in acute and chronic heart failure: a systematic review. European Journal of Heart Failure, 2017, 19, 1154-1163.	2.9	181
155	EFFECT OF SACUBITRIL/VALSARTAN COMPARED WITH ENALAPRIL, ACCORDING TO ETIOLOGY IN PARADIGM-HF. Journal of the American College of Cardiology, 2017, 69, 919.	1.2	4
156	Obesity and heart failure: when â€˜epidemicsâ€™ collide. European Heart Journal, 2017, 38, 1934-1936.	1.0	3
157	Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal, 2017, 38, 1132-1143.	1.0	160
158	The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. American Heart Journal, 2017, 188, 35-41.	1.2	32
159	Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction. Circulation, 2017, 135, 724-735.	1.6	153
160	Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. Cardiovascular Drugs and Therapy, 2017, 31, 545-549.	1.3	55
161	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. Circulation: Heart Failure, 2017, 10, .	1.6	53
162	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 877-886.	5.5	245

#	Article	IF	Citations
163	Heart Failure in Young Adults Is Associated With High Mortality: A Contemporary Population-Level Analysis. Canadian Journal of Cardiology, 2017, 33, 1472-1477.	0.8	28
164	Re-Examination of the BEST Trial Using Composite Outcomes, Including Emergency Department Visits. JACC: Heart Failure, 2017, 5, 591-599.	1.9	12
165	Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy. Circulation: Heart Failure, 2017, 10, .	1.6	53
166	Type of Atrial Fibrillation and Outcomes inÂPatients With Heart Failure and ReducedÂEjectionÂFraction. Journal of the American College of Cardiology, 2017, 70, 2490-2500.	1.2	114
167	Declining Risk of Sudden Death in Heart Failure. New England Journal of Medicine, 2017, 377, 41-51.	13.9	355
168	Dementiaâ€related adverse events in <scp>PARADIGMâ€HF</scp> and other trials in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2017, 19, 129-137.	2.9	95
169	Has the â€˜epidemicâ€™ of heart failure been replaced by a tsunami of coâ€morbidities?. European Journal of Heart Failure, 2016, 18, 500-502.	2.9	18
170	Geographic variations in the PARADIGM-HF heart failure trial. European Heart Journal, 2016, 37, 3167-3174.	1.0	114
171	Clinical outcomes according to QRS duration and morphology in the irbesartan in patients with heart failure and preserved systolic function (Iâ€PRESERVE) trial. European Journal of Heart Failure, 2016, 18, 1021-1031.	2.9	17
172	Geographic variation in heart failureâ€”a matter of celebration or condemnation?. European Journal of Heart Failure, 2016, 18, 1329-1330.	2.9	0
173	After TOPCAT: What to do now in Heart Failure with Preserved Ejection Fraction. European Heart Journal, 2016, 37, 3135-3140.	1.0	23
174	Importance of Clinical Worsening of Heart Failure Treated in the Outpatient Setting. Circulation, 2016, 133, 2254-2262.	1.6	142
175	Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure. Circulation: Heart Failure, 2016, 9, .	1.6	12
176	Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction. Circulation, 2016, 134, 1314-1324.	1.6	127
177	Return to the Workforce After First Hospitalization for Heart Failure. Circulation, 2016, 134, 999-1009.	1.6	50
178	Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to) Tj ETQq0 0 0 rgBT /Overlock 10 T Therapy. Circulation: Heart Failure, 2016, 9, .	1.6	83
179	Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for nonâ€vitamin K antagonist oral anticoagulant dose adjustment. European Journal of Heart Failure, 2016, 18, 1162-1171.	2.9	26
180	The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart, 2016, 102, 1342-1347.	1.2	139

#	Article	IF	Citations
181	Risk Related to Preâ€“Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	260
182	Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction. Circulation: Heart Failure, 2016, 9, .	1.6	93
183	Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial. International Journal of Cardiology, 2016, 209, 310-316.	0.8	22
184	Detection and prognostic value of pulmonary congestion by lung ultrasound in ambulatory heart failure patients. European Heart Journal, 2016, 37, 1244-1251.	1.0	206
185	Changes in Nâ€terminal proâ€Bâ€type natriuretic peptide levels and outcomes in heart failure with preserved ejection fraction: an analysis of the Iâ€Preserve study. European Journal of Heart Failure, 2015, 17, 809-817.	2.9	52
186	What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?. Open Heart, 2015, 2, e000283.	0.9	13
187	Assessment and prevalence of pulmonary oedema in contemporary acute heart failure trials: a systematic review. European Journal of Heart Failure, 2015, 17, 906-916.	2.9	48
188	Diagnosis and Resolution of LÃ¶effler Endocarditis Secondary to Eosinphilic Granulomatosis With Polyangiitis Demonstrated by Cardiac Magnetic Resonanceâ€“T2 Mapping. Circulation, 2015, 131, 114-117.	1.6	3
189	Estimating the Long-Term Treatment Benefits of Sacubitrilâ€“Valsartan. New England Journal of Medicine, 2015, 373, 2289-2290.	13.9	92
190	Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. European Heart Journal, 2015, 36, 939-945.	1.0	82
191	Heart Failure Management: Continuing to Fail or Signs of Success?. Cardiovascular Drugs and Therapy, 2015, 29, 5-6.	1.3	4
192	Falling Cardiovascular Mortality in HeartÂFailure With Reduced Ejection Fraction and Implications for Clinical Trials. JACC: Heart Failure, 2015, 3, 603-614.	1.9	36
193	Clinical characteristics and outcomes of patients with angina and heart failure in the <scp>CHARM</scp> (Candesartan in Heart Failure Assessment of Reduction in Mortality and) Tj ETQq1 1 0.784314 rgBT /Overlock 10	2.9	26
194	Relationship Between Alcohol Consumption and Cardiac Structure and Function in the Elderly. Circulation: Cardiovascular Imaging, 2015, 8, .	1.3	36
195	Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction. European Journal of Heart Failure, 2015, 17, 169-176.	2.9	36
196	Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individualâ€level reanalysis of CORONA and GISSIâ€HF. European Journal of Heart Failure, 2015, 17, 434-441.	2.9	39
197	Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. BMC Neurology, 2015, 15, 3.	0.8	6
198	Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation. Circulation, 2015, 131, 1486-1494.	1.6	92

#	Article	IF	Citations
199	Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. European Heart Journal, 2015, 36, 2463-2469.	1.0	29
200	Comparing LCZ696 With Enalapril According to Baseline Risk Using the MAGGIC and EMPHASIS-HF Risk Scores. Journal of the American College of Cardiology, 2015, 66, 2059-2071.	1.2	118
201	Importance of Angina in Patients With Coronary Disease, Heart Failure, and LeftÂVentricular Systolic Dysfunction. Journal of the American College of Cardiology, 2015, 66, 2092-2100.	1.2	48
202	Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina. Circulation: Heart Failure, 2015, 8, 717-724.	1.6	22
203	Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. European Heart Journal, 2015, 36, 2576-2584.	1.0	187
204	Response to Letter Regarding Article, â€œRisk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nellâ€™Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.â€• Circulation, 2015, 132, e358.	1.6	2
205	Relative Importance of History of Heart Failure Hospitalization and N-Terminal Proâ€“B-Type Natriuretic Peptide Level asÂPredictors of Outcomes in PatientsÂWithÂHeart Failure and PreservedÂEjectionÂFraction. JACC: Heart Failure, 2015, 3, 478-486.	1.9	21
206	International Geographic Variation in Event Rates in Trials of Heart Failure With Preserved and Reduced Ejection Fraction. Circulation, 2015, 131, 43-53.	1.6	75
207	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. European Heart Journal, 2015, 36, 669-675.	1.0	62
208	Elevation in High-Sensitivity Troponin T in Heart Failure and Preserved Ejection Fraction and Influence of Treatment With the Angiotensin Receptor Neprilysin Inhibitor LCZ696. Circulation: Heart Failure, 2014, 7, 953-959.	1.6	80
209	Explaining trends in Scottish coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis using routine data. BMJ, The, 2014, 348, g1088-g1088.	3.0	54
210	Low pulse pressure as a poor-manÊ¼s indicator of a low cardiac index in patients with severe cardiac dysfunction. Journal of Cardiovascular Medicine, 2014, 15, 315-321.	0.6	11
211	LGE and NT-proBNP Identify LowÂRisk of Death or Arrhythmic Events inÂPatients With Primary Prevention ICDs. JACC: Cardiovascular Imaging, 2014, 7, 561-569.	2.3	26
212	Thyroid-Stimulating Hormone and Clinical Outcomes. JACC: Heart Failure, 2014, 2, 35-40.	1.9	38
213	Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, <scp>LCZ696</scp>, in patients with heart failure with preserved ejection fraction: an analysis of the <scp>PARAMOUNT</scp> trial. European Journal of Heart Failure, 2014, 16, 671-677.	2.9	67
214	Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (Iâ€Preserve). European Journal of Heart Failure, 2014, 16, 778-787.	2.9	80
215	Relationship between angina pectoris and outcomes in patients with heart failure and reduced ejection fraction: an analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European Heart Journal, 2014, 35, 3426-3433.	1.0	18
216	Effect of Rosuvastatin on Repeat Heart Failure Hospitalizations. JACC: Heart Failure, 2014, 2, 289-297.	1.9	99

#	Article	IF	Citations
217	Fatigue as a Predictor of Outcome in Patients With Heart Failure. JACC: Heart Failure, 2014, 2, 187-197.	1.9	40
218	Heart failure in younger patients: the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). European Heart Journal, 2014, 35, 2714-2721.	1.0	71
219	Effect of Rosuvastatin on Fatigue in Patients With Heart Failure. Journal of the American College of Cardiology, 2013, 61, 1121-1122.	1.2	9
220	Clinical Characteristics and Outcomes of Young and Very Young Adults With Heart Failure. Journal of the American College of Cardiology, 2013, 62, 1845-1854.	1.2	84
221	Angina and intermittent claudication in 7403 participants of the 2003 Scottish Health Survey: Impact on general and mental health, quality of life and five-year mortality. International Journal of Cardiology, 2013, 167, 2149-2155.	0.8	19
222	How Small Is Too Small? A Systematic Review of Center Volume and Outcome After Cardiac Transplantation. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 783-790.	0.9	48
223	Heart failure and socioeconomic status: accumulating evidence of inequality. European Journal of Heart Failure, 2012, 14, 138-146.	2.9	218
224	Prior psychiatric hospitalization is associated with excess mortality in patients hospitalized with non-cardiac chest pain: a data linkage study based on the full Scottish population (1991-2006). European Heart Journal, 2012, 33, 760-767.	1.0	7
225	What Have We Learned About Patients With Heart Failure and Preserved Ejection Fraction From DIG-PEF, CHARM-Preserved, and I-PRESERVE?. Journal of the American College of Cardiology, 2012, 60, 2349-2356.	1.2	157
226	Pharmacist intervention in primary care to improve outcomes in patients with left ventricular systolic dysfunction. European Heart Journal, 2012, 33, 314-324.	1.0	93
227	Reply to the letter by Dr Erqou regarding â€œIntensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patientsâ€• American Heart Journal, 2012, 163, e37.	1.2	0
228	Remodelling of human atrial K+ currents but not ion channel expression by chronic Î²-blockade. Pflugers Archiv European Journal of Physiology, 2012, 463, 537-548.	1.3	22
229	Prior psychiatric hospitalization: an underappreciated risk factor for premature mortality among individuals with chest pain. European Heart Journal, 2012, 33, 804-6.	1.0	0
230	Heart Failure and Chronic Obstructive Pulmonary Disease. Journal of the American College of Cardiology, 2011, 57, 2127-2138.	1.2	135
231	Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: Evidence from a 37,229 patient meta-analysis. American Heart Journal, 2011, 162, 938-948.e2.	1.2	156
232	Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986 - 2005: a retrospective cohort study. BMC Neurology, 2011, 11, 38.	0.8	24
233	Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. BMC Medicine, 2010, 8, 23.	2.3	29
234	Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case-Control Study From the U.K. General Practice Research Database. Diabetes Care, 2010, 33, 1213-1218.	4.3	128

#	Article	IF	Citations
235	Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1301-1305.	0.9	37
236	Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. European Journal of Heart Failure, 2010, 12, 17-24.	2.9	84
237	Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBISâ€Ⅱ) trial. European Journal of Heart Failure, 2010, 12, 607-616.	2.9	71
238	Age- and Sex-Specific Trends in Fatal Incidence and Hospitalized Incidence of Stroke in Scotland, 1986 to 2005. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 475-483.	0.9	26
239	Sex Differences in Incidence, Mortality, and Survival in Individuals With Stroke in Scotland, 1986 to 2005. Stroke, 2009, 40, 1038-1043.	1.0	69
240	Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. European Journal of Heart Failure, 2009, 11, 130-139.	2.9	423
241	Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003. Circulation, 2009, 119, 515-523.	1.6	468
242	Heart failure and chronic obstructive pulmonary disease: lung function test interpretation: reply. European Journal of Heart Failure, 2009, 11, 632-633.	2.9	0
243	Discordant Short- and Long-Term Outcomes Associated With Diabetes in Patients With Heart Failure: Importance of Age and Sex. Circulation: Heart Failure, 2008, 1, 234-241.	1.6	57
244	Heart Failure After Acute Myocardial Infarction. Circulation, 2008, 118, 2019-2021.	1.6	90
245	A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart, 2007, 93, 606-612.	1.2	154
246	Effect of socioeconomic deprivation on the population risk of incident heart failure hospitalisation: An analysis of the Renfrew/Paisley Study. European Journal of Heart Failure, 2006, 8, 856-863.	2.9	37
247	Does Aspirin Reduce the Benefit of an Angiotensin-Converting Enzyme Inhibitor?. Circulation, 2006, 113, 2566-2568.	1.6	12
248	Aspirin Inhibits the Acute Arterial and Venous Vasodilator Response to Captopril in Patients with Chronic Heart Failure. Cardiovascular Drugs and Therapy, 2005, 19, 261-265.	1.3	12
249	17ÃŸ Oestradiol Does Not Attenuate the Response to Angiotensin I and II During Long Term Therapy in Postmenopausal Women. Cardiovascular Drugs and Therapy, 2004, 18, 31-36.	1.3	2
250	Attenuation of endothelin-1 induced vasoconstriction by 17Î² estradiol is not sustained during long-term therapy in postmenopausal women with coronary heart disease. Journal of the American College of Cardiology, 2001, 37, 1367-1373.	1.2	23
251	Aspirin inhibits the acute venodilator response to furosemide in patients with chronic heart failure. Journal of the American College of Cardiology, 2001, 37, 1234-1238.	1.2	32
252	The acute vascular effects of frusemide in heart failure. British Journal of Clinical Pharmacology, 2000, 50, 9-13.	1.1	30